Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.48165/3e51d373Keywords:
Dapagliflozin, Oral hypoglycemic drug, Diabetes MellitusAbstract
Background: To assess effectiveness of Dapagliflozin as add-on therapy for the treatment of Type 2 Diabetes Mellitus. Method: Dapaglifozin was added as add on treatment in all the patients after the initial standard management. They were divided into groups based on the initial combinations with comparable baseline readings for HbA1c and fasting blood glucose (FBG). Differences in the values of HbA1c and FBG following treatment with Dapagliflozin was evaluated at 3 months. Result: Among all 130 subjects, the 56.92% were males and 43.08% were females. Maximum subjects belonged to the age group of 50-59 years. The mean age of the subjects was 54.02 years. Out of 130 subjects, 29.23% had a history of T2DM. Most of the subjects had T2DM from last 8-10 years (53.08%), Out of 130 subjects, 16.92% had hypertension, 10.77% had cardiovascular disease and 6.15% had other co-morbidities. The mean body weight and height among the subjects after the intervention was 68.96Kg and 162.09 respectively. Glycemic parameters among the study subjects after the intervention showed a mean HbA1c value of 7.05%, mean FBG value of 131.73mg/dl and mean PPBG value of 204.98mg/dl. Mean HbA1c level achieved after 6 months of Dapagliflozin treatment was 7.62% in our patient population. Conclusion: Dapagliflozin was well tolerated in patients with T2DM and it lowered HbA1c levels and body weight after the intervention compared to baseline. The study found no adverse effect, implying that Dapaglifozin has a tolerable tolerability profile.
References
1. Khursheed R, Singh SK, Wadhwa S, Kapoor B, Gulati M, Kumar R, et al. Treatment strategies against diabetes: Success so far and challenges ahead. Eur J Pharmacol. 2019;862:172625. Available from: https://doi.org/10.1016/j. ejphar.2019.172625.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. Available from: https://doi.org/10.2337/diacare.27.5.1047.
3. Clar C, Gill JA, Court R. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2(5):1007.
4. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559. Available from: https://doi.org/10.1038/nrd3180.
5. Hu L, Zhou ZY. Research progress of sodium-glucose co-transporter-2 inhibitor drugs. Med Recapitulate. 2011;12:3782–3787.
6. Defronzo RA, Davidson JA, Prato SD. The role of the kidneys
glycaemia. Diabetes Obes Metab. 2012;14(1):5–14. Available from: https://doi.org/10.1111/j.1463-1326.2011.01511.x. 7. Meng W, Ellsworth BA, lexandra A Nirschl, McCann PJ, Patel M, Girotra RN, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51(5):1145–1149. Available from: https: //doi.org/10.1021/jm701272q.
8. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723–1729. Available from: https://doi.org/10. 2337/db07-1472.
9. Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med. 2013;125(3):181–189. Available from: https://doi.org/10. 3810/pgm.2013.05.2667.
10. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520–526. Available from: https: //doi.org/10.1038/clpt.2008.251.
11. Morales-Chávez MC, Rueda-Delgado YM, Da PO. Prevalence of bucco-dental pathologies in patients with psychiatric dis orders. J Clin Exp Dent. 2014;6(1):7–11. Available from: https://dx.doi.org/10.4317/jced.51147.
12. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mel litus: a review of current trends. Oman Med J. 2012;27(4):269– 273. Available from: https://dx.doi.org/10.5001/omj.2012.68.
13. Joaqui VB, Gómez NB, Ortiz RC, Toro LM, Lombo JP, Cifuentes CA, et al. Effectiveness of triple therapy with
dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity. Arch Endocrinol Metab. 2021;65(1):49–59. Avail able from: https://doi.org/10.20945/2359-3997000000319.
14. Viswanathan V, Singh KP. Use of Dapagliflozin in the management of type 2 diabetes mellitus: a real-world evidence study in Indian patients (FOREFRONT). Diabetes Technol Ther. 2019;21(8):415–422. Available from: https://doi.org/10. 1089/dia.2019.0052.
15. Ketema EB, Kibret KT. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Arch Public Health. 2015;73:43. Available from: https://dx.doi.org/10.1186/ s13690-015-0088-6.
